Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Roka BioScience, Inc. (ROKA)
|
Add to portfolio |
|
|
|
| Price: |
$0.65
| | Metrics |
| OS: |
5.01
|
M
| |
-310
|
% ROE
|
| Market cap: |
$3.25
|
M
| |
-470
|
% ROIC
|
|
Net cash:
|
$1.15
|
M
| |
$0.23
|
per share
|
|
EV:
|
$2.11
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($14.6)
|
M
| |
|
|
|
EBIT
|
($20.2)
|
M
| |
|
|
| EPS |
($11.10)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 7.2 | 6.0 | 5.1 | 2.2 | 0.1 |
| Revenue growth | 21.0% | 18.4% | 131.8% | 1978.1% | |
| Cost of goods sold | 8.0 | 7.7 | 7.8 | 6.6 | 3.2 |
| Gross profit | -0.7 | -1.7 | -2.8 | -4.4 | -3.1 |
| Gross margin | -10.1% | -28.7% | -55.2% | -202.5% | -2934.3% |
| Selling, general and administrative | 17.7 | 21.8 | 19.1 | 17.5 | 16.1 |
| Research and development | 7.3 | 7.7 | 7.9 | 7.6 | 9.6 |
| EBITA | -25.7 | -31.2 | -29.8 | -29.5 | -28.7 |
| EBITA margin | -355.2% | -521.1% | -589.8% | -1350.5% | -27349.5% |
| Amortization of intangibles | 3.8 | 3.7 | 1.8 | 0.2 | 0.2 |
| EBIT | -29.5 | -34.9 | -31.6 | -29.6 | -28.9 |
| EBIT margin | -407.1% | -583.7% | -624.7% | -1358.2% | -27509.5% |
| Pre-tax income | -31.0 | -37.3 | -34.2 | -32.7 | -24.0 |
| Income taxes | -0.2 | -0.7 | -2.0 | -3.1 | -0.8 |
| Tax rate | 0.8% | 1.9% | 5.7% | 9.5% | 3.3% |
| Net income | -38.5 | -36.6 | -32.2 | -29.6 | -23.2 |
| Net margin | -532.1% | -611.5% | -637.3% | -1355.5% | -22139.0% |
| |
| Diluted EPS | ($17.42) | ($21.18) | ($29.30) | ($56.88) | ($70.54) |
| Shares outstanding (diluted) | 2.2 | 1.7 | 1.1 | 0.5 | 0.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|